Genetic testing (e.g., SCN1A mutations as a diagnostic biomarker for Dravet syndrome, Neuroimaging tools, Multimodal imaging co-registration tools, Automated detection of brain abnormalities in MRI, Quantitative evaluation of Neuroimaging, invasive and non-invasive EEG data, Detection of autoantibodies in autoimmune epilepsies). Here, SCN1A is linked to encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy.